BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35180471)

  • 21. Autophagy inhibition re-sensitizes pulse stimulation-selected paclitaxel-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis.
    Wen J; Yeo S; Wang C; Chen S; Sun S; Haas MA; Tu W; Jin F; Guan JL
    Breast Cancer Res Treat; 2015 Feb; 149(3):619-29. PubMed ID: 25638397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer.
    Liao L; Zhang YL; Deng L; Chen C; Ma XY; Andriani L; Yang SY; Hu SY; Zhang FL; Shao ZM; Li DQ
    Cancer Res; 2023 Feb; 83(3):471-484. PubMed ID: 36484700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease.
    Sato K; Padgaonkar AA; Baker SJ; Cosenza SC; Rechkoblit O; Subbaiah DRCV; Domingo-Domenech J; Bartkowski A; Port ER; Aggarwal AK; Ramana Reddy MV; Irie HY; Reddy EP
    Nat Commun; 2021 Aug; 12(1):4671. PubMed ID: 34344863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein kinase C inhibitor chelerythrine selectively inhibits proliferation of triple-negative breast cancer cells.
    Lin W; Huang J; Yuan Z; Feng S; Xie Y; Ma W
    Sci Rep; 2017 May; 7(1):2022. PubMed ID: 28515445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models.
    Cocco S; Leone A; Roca MS; Lombardi R; Piezzo M; Caputo R; Ciardiello C; Costantini S; Bruzzese F; Sisalli MJ; Budillon A; De Laurentiis M
    J Transl Med; 2022 Jun; 20(1):290. PubMed ID: 35761360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TNFSF13 upregulation confers chemotherapeutic resistance via triggering autophagy initiation in triple-negative breast cancer.
    Lin HY; Kuei CH; Lee HH; Lin CH; Chen YL; Chen CL; Lin YF
    J Mol Med (Berl); 2020 Sep; 98(9):1255-1267. PubMed ID: 32671412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Curcumin inhibits the growth of triple-negative breast cancer cells by silencing EZH2 and restoring DLC1 expression.
    Zhou X; Jiao D; Dou M; Zhang W; Lv L; Chen J; Li L; Wang L; Han X
    J Cell Mol Med; 2020 Sep; 24(18):10648-10662. PubMed ID: 32725802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of FOXO1‑mediated autophagy promotes paclitaxel‑induced apoptosis of MDA‑MB‑231 cells.
    Xu K; Zhu W; Xu A; Xiong Z; Zou D; Zhao H; Jiao D; Qing Y; Jamal MA; Wei HJ; Zhao HY
    Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 35014689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
    Jurj A; Pop LA; Zanoaga O; Ciocan-Cârtiţă CA; Cojocneanu R; Moldovan C; Raduly L; Pop-Bica C; Trif M; Irimie A; Berindan-Neagoe I; Braicu C
    Cell Physiol Biochem; 2020 Jul; 54(4):648-664. PubMed ID: 32619350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway.
    Wang L; Zhou Y; Jiang L; Lu L; Dai T; Li A; Chen Y; Zhang L
    Mol Cancer; 2021 Mar; 20(1):43. PubMed ID: 33648498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
    Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
    Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance.
    Zong B; Sun L; Peng Y; Wang Y; Yu Y; Lei J; Zhang Y; Guo S; Li K; Liu S
    Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34036395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radix Tetrastigma Extracts Enhance the Chemosensitivity in Triple-Negative Breast Cancer Via Inhibiting PI3K/Akt/mTOR-Mediated Autophagy.
    Zhang S; Cui T; Duan Y; Zhang H; Wang B; Chen H; Ni J; Shen Y; Xiao-Ai Lv
    Clin Breast Cancer; 2022 Feb; 22(2):89-97. PubMed ID: 34535390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Knockdown of SERPINE1 reverses resistance of triple‑negative breast cancer to paclitaxel via suppression of VEGFA.
    Zhang Q; Lei L; Jing D
    Oncol Rep; 2020 Nov; 44(5):1875-1884. PubMed ID: 33000256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual Inhibition of Key Proliferation Signaling Pathways in Triple-Negative Breast Cancer Cells by a Novel Derivative of Taiwanin A.
    Kuo YH; Chiang EI; Chao CY; Rodriguez RL; Chou PY; Tsai SY; Pai MH; Tang FY
    Mol Cancer Ther; 2017 Mar; 16(3):480-493. PubMed ID: 27956520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer.
    Oudin MJ; Barbier L; Schäfer C; Kosciuk T; Miller MA; Han S; Jonas O; Lauffenburger DA; Gertler FB
    Mol Cancer Ther; 2017 Jan; 16(1):143-155. PubMed ID: 27811011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
    Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
    Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy.
    Ma ZR; Xiong QW; Cai SZ; Ding LT; Yin CH; Xia HL; Liu W; Dai S; Zhang Y; Zhu ZH; Huang ZJ; Wang Q; Yan XM
    Int Immunopharmacol; 2023 Sep; 122():110617. PubMed ID: 37478666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
    Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
    Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.